...
首页> 外文期刊>Psychopharmacology >Comparison of the effects of clozapine and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on progressive ratio schedule performance: evidence against the involvement of 5-HT1A receptors in the behavioural effects of clozapine.
【24h】

Comparison of the effects of clozapine and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on progressive ratio schedule performance: evidence against the involvement of 5-HT1A receptors in the behavioural effects of clozapine.

机译:氯氮平和8-羟基-2-(二-正丙基氨基)四氢化萘(8-OH-DPAT)对渐进式配比计划性能影响的比较:反对5-HT1A受体参与氯氮平行为影响的证据。

获取原文
获取原文并翻译 | 示例
           

摘要

RATIONALE: Performance on progressive ratio schedules has been proposed as a means of assessing the effects of drugs on the efficacy of reinforcers. A mathematical model (Killeen PR (1994) Mathematical principles of reinforcement. Behav Brain Sci 17:105-172) affords a basis for quantifying the effects of drugs on progressive ratio schedule performance. The model postulates a bitonic function relating response rate and ratio size. One parameter of the function, a, expresses the motivational effect of the reinforcer, whereas another parameter, delta, expresses the minimum time needed to execute a response, and is regarded as an index of 'motor capacity'. Previously we found that the atypical antipsychotic clozapine increased a, indicating an increase in reinforcer efficacy; a similar effect was observed with the 5-hydroxytryptamine (5-HT)(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). It has been suggested that some of clozapine's behavioural effects are mediated by agonistic action at 5-HT(1A) receptors. OBJECTIVE: This study was conducted to compare the effects of clozapine and 8-OH-DPAT on progressive ratio schedule performance. METHODS: Rats were trained under a time-constrained progressive ratio schedule (50-min sessions). In experiment 1, they received acute doses of clozapine (4 mg kg(-1)) and 8-OH-DPAT (100 microg kg(-1)), alone and in combination with the 5-HT(1A) receptor antagonist N-[2-(4-[2-methoxyphenyl]-1-piperazinyl)ethyl]-N-2-yridinylcyclohexanecarb oxamide (WAY-100635; 30 microg kg(-1)). In experiment 2, the effects of clozapine (2, 4 and 8 mg kg(-1)) and 8-OH-DPAT (25, 50 and 100 microg kg(-1)) were compared between intact rats and rats whose 5-HTergic pathways had been ablated by 5,7-dihydroxytryptamine (5,7-DHT). RESULTS: In both experiments, clozapine and 8-OH-DPAT increased a and delta. In experiment 1, WAY-100635 abolished the effect of 8-OH-DPAT on a and delta, but did not alter clozapine's effects on these parameters. In experiment 2, the effects of clozapine and 8-OH-DPAT did not differ between sham-lesioned and 5,7-DHT-lesioned rats. CONCLUSIONS: The results confirm previous findings on the effects of clozapine and 8-OH-DPAT on progressive ratio schedule performance. 8-OH-DPAT's effects are probably mediated by post-synaptic 5-HT(1A) receptors; clozapine's effects are mediated by a different mechanism, which does not appear to involve 5-HT(1A) receptors and which does not depend upon an intact 5-HTergic pathway.
机译:理由:已提出按渐进比例表进行评估,作为评估药物对增强药疗效的一种手段。数学模型(Killeen PR(1994)强化的数学原理。Behav Brain Sci 17:105-172)提供了量化药物对渐进式比例进度表现的影响的基础。该模型假设一个与响应率和比率大小相关的双音函数。函数的一个参数a表示增强器的激励作用,而另一个参数delta表示执行响应所需的最短时间,并被视为“运动能力”的指标。先前我们发现非典型的抗精神病药物氯氮平增加了a,表明增强剂的功效增加了。用5-羟基色胺(5-HT)(1A)受体激动剂8-羟基-2-(二-正丙基氨基)四氢化萘(8-OH-DPAT)观察到了类似的效果。有人提出,氯氮平的某些行为影响是通过对5-HT(1A)受体的激动作用介导的。目的:本研究旨在比较氯氮平和8-OH-DPAT对进度比进度表的影响。方法:在有时间限制的渐进比例表(50分钟训练)下训练大鼠。在实验1中,他们分别接受急性剂量的氯氮平(4 mg kg(-1))和8-OH-DPAT(100 microg kg(-1)),并与5-HT(1A)受体拮抗剂N联合使用-[[2-(4- [2-甲氧基苯基] -1-哌嗪基)乙基] -N-2-吡啶基环己烷碳氧酰胺(WAY-100635; 30微克kg(-1))。在实验2中,比较了完整大鼠和5只大鼠的氯氮平(2、4和8 mg kg(-1))和8-OH-DPAT(25、50和100 microg kg(-1))的作用。 HTergic途径已被5,7-二羟基色胺(5,7-DHT)消除。结果:在两个实验中,氯氮平和8-OH-DPAT均增加了α和δ。在实验1中,WAY-100635取消了8-OH-DPAT对α和δ的影响,但并未改变氯氮平对这些参数的影响。在实验2中,氯氮平和8-OH-DPAT的作用在假手术和5,7-DHT受伤的大鼠之间没有差异。结论:该结果证实了先前关于氯氮平和8-OH-DPAT对进行性比率计划表现的影响的发现。 8-OH-DPAT的作用可能是由突触后的5-HT(1A)受体介导的。氯氮平的作用是由不同的机制介导的,该机制似乎不涉及5-HT(1A)受体,并且不依赖于完整的5-HTergic途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号